WO1996031231A1 - Controlled release biodegradable nanoparticles containing insulin - Google Patents
Controlled release biodegradable nanoparticles containing insulin Download PDFInfo
- Publication number
- WO1996031231A1 WO1996031231A1 PCT/IE1996/000018 IE9600018W WO9631231A1 WO 1996031231 A1 WO1996031231 A1 WO 1996031231A1 IE 9600018 W IE9600018 W IE 9600018W WO 9631231 A1 WO9631231 A1 WO 9631231A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- nanoparticles
- controlled release
- polyalkylcyanoacrylate
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
Definitions
- This invention relates to controlled release biodegradable nanoparticle formulations and, in particular, biodegradable polyalkylcyanoacrylate nanoparticles containing insulin or insulin analogues.
- Polyalkylcyanoacrylate nanoparticles have been studied as potential drug carriers for sustained release formulations, for drug targeting and for improving the bioavailability of peptides and proteins such as insulin, calcitonin and growth hormone releasing factor (Damg ⁇ , C. et al, Diabetes, 37:246(51) (1988); Lowe, P. et al., J. Pharma. Pharmacol., 46:547-52 (1994); and Gautier, J. et al., J. Controlled Release, 20:67-78 (1992)).
- the short chain cyanoacrylate monomers such as n-butyl, isobutyl and isohexylcyanoacrylate, are typically used because of their short degradation times and low toxicities.
- interfacial polymerisation method Two methods are commonly employed for the preparation of these nanoparticles: the interfacial polymerisation method and the anionic polymerisation method.
- the interfacial polymerisation method the monomer and the drug are dissolved in an organic phase with polymerisation occurring at the organic-aqueous interface upon addition of the organic phase to an aqueous phase (Al Khouri, N. et al., Int. J. Pharm., 28:125-32 (1986).
- This method produces nanocapsules.
- prior art peptide loaded nanoparticles have been produced by this technique (see, e.g., EP-A-0 608 207; EP-A-0 447 318; and FR- A-2,515,960).
- Anionic polymerisation occurs in aqueous media at low pH and is catalyzed by hydroxyl ions.
- the drug can be incorporated within the nanoparticle, adsorbed onto the nanoparticles or a combination of both depending on the time of addition of the drug to the polymerisation medium (Couvreur, P. et al., J. Pharma. Pharmacol, 31:331-2 (1979)).
- Vidarabine-associated polyalkylcyanoacrylate nanoparticles which result from vidarabine chemically interacting with the cyanoacrylic monomer during the polymerisation process, have been made using the anionic polymerisation method modified by the mandatory inclusion of dioctylsulfosuccinate in the aqueous media.
- formation of the polyalkylcyanoacrylate/vidarabine complex inactivated the biological activity of the vidarabine (Guise, V., et al., Pharmaceutical Res., 7:736-41 (1990)).
- exogenous insulin can ameliorate metabolic abnormalities in type II diabetes by compensating for reduced endogenous insulin secretion, reducing excessive hepatic glucose production and stimulating glucose uptake. Additionally, non- substitutional insulin administration in non-insulin dependent diabetes is indicated where, without it, satisfactory compensation of diabetes is not achieved. Side effects possible from insulin therapy include weight gain, hyperinsulinemia and hypoglycemia.
- This invention provides a controlled release pharmaceutical formulation, which comprises insulin entrapped in a biodegradable polyalkylcyanoacrylate polymer to form nanoparticles, wherein the insulin is complexed to the polyalkylcyanoacrylate.
- insulin refers to insulin and analogues of insulin having similar physical properties.
- polyalkylcyanoacrylate refers to poly(2-12 C (straight or branched chain) alkyl 2-cyanoacrylates.
- Preferred polyalkylcyanoacrylates include polymers formed from 4-6 C alkylcyanoacrylate monomers such as n-butylcyanoacrylate, isobutylcyanoacrylate and isohexylcyanoacrylate or mixtures thereof.
- biodegradable as applied to polyalkyl ⁇ cyanoacrylate polymers means polymers which are degradable in vivo either enzymatically or non-enzymatically to produce biocompatible or non-toxic by-products which can be further metabolized or excreted via normal physiological pathways.
- the biodegradable polyalkylcyanoacrylate polymer is suitably n- butylcyanoacrylate, isobutylcyanoacrylate or isohexylcyanoacrylate monomers or mixtures thereof.
- this invention discloses that at low pH and otherwise typical anionic polymerisation conditions, insulin complexes with polycyanoacrylate during the polymerisation step, forming polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles.
- the insulin does not complex with the polymer but, rather, is incorporated into nanoparticles as free insulin.
- the polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles are capable of releasing bioactive insulin in vivo. The rate of insulin release from these polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles is slower than that from corresponding free insulin- loaded polyalkylcyanoacrylate nanoparticles.
- the nanoparticles can be a natural mixture of free and complexed insulin.
- this invention provides oral and parenteral formulations containing polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles that are capable of releasing pharmaceutically effective amounts of bioactive insulin in a controlled fashion to satisfy physiological insulin needs when orally or parenterally administered to a subject, particularly a human. Further, the controlled release nature of these formulations makes possible the targeting of insulin to the small intestine when administered orally, which enhances the bioavailability of the insulin.
- these oral and parenteral formulations may comprise a mixture of polyalkylcyanoacrylate- complexed insulin-loaded nanoparticles and free insulin-loaded polyalkylcyanoacrylate nanoparticles.
- the biodegradable nanoparticles preferably contain 5% to 30% w/v of insulin to monomer content, more especially 15-25% w/v insulin.
- the size of the biodegradable nanoparticles suitably is 50-900 nm, preferably 100-400 nm.
- the polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles in accordance with the invention and, optionally, free insulin-loaded polyalkylcyanoacrylate nanoparticles, if present, are suitably incorporated into oral dosage forms, such as capsules, tablets, powders including powders capable of effervescing upon addition of water, or suspensions.
- an enteric coating can be applied to the polyalkylcyanoacrylate-complexed insulin-loaded nanoparticles and, optionally, free insulin-loaded polyalkylcyanoacrylate nanoparticles, if present, to protect the formulation while it passes though the stomach to further target release of insulin to the small intestine.
- the nanoparticles can be administered parenterally to release insulin to mimic physiological insulin needs.
- compositions of this invention can be tabletted with one or more excipient(s), encased in capsules such as gel capsules, formulated with ingredients which upon addition of water, provide an effervescent solution, and suspended in a liquid solution and the like.
- excipient(s) encased in capsules such as gel capsules
- ingredients which upon addition of water, provide an effervescent solution, and suspended in a liquid solution and the like.
- the nanoparticles can be suspended in a saline solution or the like for parenteral administration.
- the tablets optionally comprise an enteric coating on the tablet to target release of insulin to the small intestine when administered orally.
- the pharmaceutical formulations in accordance with the invention can be used inter alia to provide exogenous insulin to patients with type II diabetes or to treat non- insulin dependent diabetes.
- the formulations of this invention are administered to humans at an insulin dose, which varies from individual to individual, such that the blood glucose levels are adjusted to stay within normal ranges.
- the oral formulations preferably are designed as 4-times daily products while the parenteral formulations, which typically have >100 IU of bioavailable insulin per ml, can be administered once or twice daily up to once weekly.
- Figure 1 shows the mechanistic pathway for the anionic polymerisation method of forming polyalkylcyanoacrylate nanoparticles
- n-butylcyanoacrylate was donated by Loctite Ltd. (Ireland). Isobutylcyanoacrylate, Dextran 10, 40 and 70 and insulin (bovine) were obtained from Sigma. Surface morphology of the nanoparticles produced was studied by scanning electron microscopy (SEM) (Leica Cambridge S360). Drug loading was monitored by the method of residuals using UV spectroscopy and by gradient HPLC analysis according to USP XXII. Male Wistar rats were used in the in vivo studies and blood glucose levels were monitored by an AmesTM Glucostix system.
- Biodegradable polyalkylcyanoacrylate nanoparticles were produced from n-and isobutylcyanoacrylate using the anionic polymerisation method under standard conditions. For instance, for 20% starting drug loading, 100 mg of insulin was dissolved in 49.5 ml of a 0.01M HC1 solution containing 0.5% Dextran 70 (as a stabiliser) prior to addition of the monomer. After adding the monomer, e.g., 0.5 ml isobutylcyanoacrylate, the solution was stirred for 4 hours, filtered or centrifuged and dried overnight. No difference in particle mo ⁇ hology between particles formed from n- or isobutylcyanoacrylate was observed under these conditions.
- the surface of particles produced was smooth and free of drug crystals and the particles were 100 nm - 400 nm in diameter.
- insulin loading values 17.82% for w-butylcyanoacrylate and 17.97% for isobutylcyanoacrylate were obtained.
- the formation of insulin- loaded nanoparticles was not influenced by the choice of these monomers.
- Nanoparticles were produced using the method outlined in
- Insulin-loaded n-butylcyanoacrylate nanoparticles were produced using the method outlined in Example 1 to study the effect of varying the pH of the polymerisation medium from 1 to 4.8 on nanoparticle formation. As the pH of the polymerisation medium was increased above 3, defined, distinct particles were produced having smooth, drug- crystal free surfaces. However, below a pH of 3, formation of distinct nanoparticles appeared to be limited, showing only small quantities of well-formed nanoparticles. At this low pH, the formation of particles occurs quickly, resulting in the majority of nanoparticles not being well formed.
- HPLC analysis of insulin content of the nanoparticles produced at pH 2 yielded no insulin peaks at the expected insulin retention time.
- UV analysis by the method of residuals indicated >80% drug entrapment.
- HPLC analysis of nanoparticles produced at pH 4.8 showed the presence of insulin at the expected retention time of 19 minutes.
- Nanoparticles were produced at pH 2, 3 and 4 under the same conditions as those employed for the insulin-loaded nanoparticles. In all cases, the nanoparticles produced were smooth, spherical and uniform in size. Thus, at low pH, the presence of insulin in the polymerisation medium interferes with nanoparticle formation.
- the bioactivity and release properties of the insulin-loaded n- butylcyanoacrylate nanoparticles produced according to Example 3 were examined by intramuscular (IM) administration to male Wistar rats.
- Insulin-loaded nanoparticles produced at pH 2 (16 IU) and pH 4.8 ( 16 IU) were administered in aqueous suspension by IM injection to two groups of rats and blood glucose levels were monitored over a six hour period.
- Pure insulin solution (2.5 IU) was administered by IM injection to a third group of rats to provide a comparison between delivery via the nanoparticulate formulations and unencapsulated insulin.
- the blood glucose levels of untreated rats (controls) were also monitored over the same time period.
- Figure 2 shows the blood glucose levels for the pH 2, pH 4.8, control and untreated groups expressed as a percentage of baseline values. Blood glucose levels in the untreated group were within 87.6 to 108.9% of the baseline value in the study period.
- Administration of the nanoparticles resulted in a steady reduction in blood glucose levels to 20% of the baseline value, indicating that the insulin from both types of nanoparticles (complexed at pH 2; free insulin at pH 4.8) is bioactive and is released in a controlled, sustained fashion.
- the blood glucose reduction was faster for nanoparticles produced at pH 4.8 than for those produced at pH 2, presumably due to the faster release of free insulin from the pH 4.8 formulation as opposed to the slower release of insulin complexed with polyalkylcyanoacrylate in the pH 2 formulation.
- the bioactivity and release properties of the insulin-loaded n- butylcyanoacrylate nanoparticles produced according to Example 3 were examined by oral administration to male Wistar rats.
- Insulin- loaded nanoparticles produced at pH 2 were administered orally in an aqueous suspension to a group of rats and blood glucose levels were monitored over a four hour period.
- the dose administered per rat was 204 IU of insulin.
- the blood glucose levels of untreated rats were also monitored over the same time period.
- Figure 3 shows the blood glucose levels for these two groups expressed as a percentage of baseline values. Blood glucose levels in untreated rats were between 85 and 100% of the baseline value during the study period. In the treated rats, a reduction in blood glucose levels to 35% of the baseline value was observed over a four hour period giving an oral bioavailability of >7% for these insulin-loaded nanoparticles.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT96909320T ATE261311T1 (en) | 1995-04-04 | 1996-04-02 | BIODEGRADABLE NANOPARTICLES WITH CONTROLLED RELEASE OF INSULIN |
NZ304976A NZ304976A (en) | 1995-04-04 | 1996-04-02 | Controlled release biodegradable nanocapsules containing insulin |
DE69631824T DE69631824T2 (en) | 1995-04-04 | 1996-04-02 | BIODEGRADABLE NANOPARTICLES WITH CONTROLLED RELEASE OF INSULIN |
CA002217485A CA2217485C (en) | 1995-04-04 | 1996-04-02 | Controlled release biodegradable nanoparticles containing insulin |
EP96909320A EP0820300B1 (en) | 1995-04-04 | 1996-04-02 | Controlled release biodegradable nanoparticles containing insulin |
AU52867/96A AU704875B2 (en) | 1995-04-04 | 1996-04-02 | Controlled release biodegradable nanoparticles containing insulin |
JP53015796A JP3981152B2 (en) | 1995-04-04 | 1996-04-02 | Controlled release of biodegradable nanoparticles containing insulin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE950237A IE80468B1 (en) | 1995-04-04 | 1995-04-04 | Controlled release biodegradable nanoparticles containing insulin |
IE950237 | 1995-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996031231A1 true WO1996031231A1 (en) | 1996-10-10 |
Family
ID=11040701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IE1996/000018 WO1996031231A1 (en) | 1995-04-04 | 1996-04-02 | Controlled release biodegradable nanoparticles containing insulin |
Country Status (14)
Country | Link |
---|---|
US (1) | US5641515A (en) |
EP (1) | EP0820300B1 (en) |
JP (1) | JP3981152B2 (en) |
AT (1) | ATE261311T1 (en) |
AU (1) | AU704875B2 (en) |
CA (1) | CA2217485C (en) |
DE (1) | DE69631824T2 (en) |
DK (1) | DK0820300T3 (en) |
ES (1) | ES2213770T3 (en) |
IE (1) | IE80468B1 (en) |
NZ (1) | NZ304976A (en) |
PT (1) | PT820300E (en) |
WO (1) | WO1996031231A1 (en) |
ZA (1) | ZA962671B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001039794A1 (en) * | 1999-11-30 | 2001-06-07 | Oao 'quantum Satis' | Insulin-containing medicament for peroral application and method for the production thereof |
JP2002504526A (en) * | 1998-02-27 | 2002-02-12 | バイオオーリアンス ファーマ(エス.エー.) | Nanoparticles comprising at least one polymer and at least one compound capable of complexing with one or more active ingredients |
US6582713B2 (en) | 2000-04-06 | 2003-06-24 | Univ. Of Colorado - Colorado Springs | Compositions and methods for promoting wound healing |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
WO2005034909A2 (en) * | 2003-10-02 | 2005-04-21 | Complex Biosystems Gmbh | Hyperbranched polymer conjugates via non-enzymatic cleavable linker |
FR2872703A1 (en) * | 2004-07-07 | 2006-01-13 | Ethypharm Sa | COMPOSITE POLYMERIC NANOPARTICLES |
WO2008003706A1 (en) * | 2006-07-04 | 2008-01-10 | Nanodel Technologies Gmbh | Two step miniemulsion process |
EP2236143A1 (en) * | 2007-12-27 | 2010-10-06 | Public University Corporation Yokohama City University | Antimicrobial agent for gram-positive bacteria |
EP2285825A1 (en) * | 2008-05-09 | 2011-02-23 | South Dakota State University | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
WO2013171570A1 (en) * | 2012-05-16 | 2013-11-21 | Glaxo Group Limited | Polypeptide loaded poca nanoparticles for oral administration |
WO2014027254A1 (en) * | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
WO2014027253A1 (en) * | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
EP2805617A4 (en) * | 2012-01-19 | 2015-08-12 | Shoichi Shirotake | Antibacterial agent against plant disease-causing bacteria |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US10351644B2 (en) | 2014-02-27 | 2019-07-16 | Shoichi Shirotake | Antiviral drug |
Families Citing this family (340)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5985312A (en) * | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US6120806A (en) * | 1997-06-25 | 2000-09-19 | Whitmire; David R. | Oral formulations for controlled release of alcohol deterrents |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
US20040259895A1 (en) * | 1998-05-28 | 2004-12-23 | Medical Research Institute | Oral formulation of lipid soluble thiamine and lipoic acid |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
EP2266542A3 (en) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
EP1135682B1 (en) | 1998-11-30 | 2007-07-11 | Nanosphere, Inc. | Nanoparticles with polymer shells |
US20040258763A1 (en) * | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
US20020054914A1 (en) * | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
PT1178952E (en) | 1999-05-14 | 2007-12-04 | Univ California | Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
EP1754488A1 (en) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
EP1259608B1 (en) | 2000-02-23 | 2009-08-12 | Life Technologies Corporation | Modified fluorescent proteins |
CA2400842C (en) | 2000-02-23 | 2013-01-15 | Smithkline Beecham Biologicals S.A. | Novel compounds |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US10293056B1 (en) | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
CA2309575A1 (en) * | 2000-05-26 | 2001-11-26 | James E. Guillet | Internally cross-linked macromolecules |
DK2133100T3 (en) | 2000-06-20 | 2012-01-23 | Corixa Corp | MTB32A Antigen of Mycobacterium tuberculosis with Inactivated Active Site and Fusion Proteins |
ATE396265T1 (en) | 2000-06-28 | 2008-06-15 | Corixa Corp | COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER |
US6602523B1 (en) | 2000-08-17 | 2003-08-05 | Technology Holding, Llc. | Composite material and process for increasing bioavailability and activity of a beneficial agent |
JP4395549B2 (en) * | 2000-11-16 | 2010-01-13 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | Marine actinomycete taxa for the discovery of drugs and fermentation products |
CA2429769C (en) * | 2000-12-07 | 2016-04-26 | Board Of Regents, The University Of Texas System | Methods of treatment involving human mda-7 |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US6607784B2 (en) * | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
JP2005504513A (en) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of prostate cancer |
US20030185892A1 (en) * | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
US20030095928A1 (en) * | 2001-09-19 | 2003-05-22 | Elan Pharma International Limited | Nanoparticulate insulin |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20040009939A1 (en) * | 2002-03-05 | 2004-01-15 | Board Of Regent, The University Of Texas System | Methods of enhancing immune induction involving MDA-7 |
AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
US7332469B2 (en) | 2002-04-05 | 2008-02-19 | Board Of Regents The University Of Texas System | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
EP2269619A1 (en) | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
US7112581B2 (en) * | 2002-09-27 | 2006-09-26 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
US20050051968A1 (en) * | 2002-11-13 | 2005-03-10 | Froesel David William | Washer toss game |
EP1576138B1 (en) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
WO2004056311A2 (en) * | 2002-12-17 | 2004-07-08 | Massachusetts Institute Of Technology | Stimuli-responsive systems for controlled drug delivery |
MXPA05007295A (en) | 2003-01-06 | 2005-09-30 | Corixa Corp | Certain aminoalkyl glucosaminide phosphate compounds and their use. |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
ATE513551T1 (en) * | 2003-01-24 | 2011-07-15 | Flora Technology Inc | COMPOSITIONS AND METHODS FOR RESTORING BACTERIAL FLORA |
CA2518150C (en) * | 2003-03-03 | 2015-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions involving mda-7 |
CA2529623A1 (en) * | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US20050049294A1 (en) * | 2003-06-20 | 2005-03-03 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
EP2567693B1 (en) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering RNA |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
AU2004285477A1 (en) | 2003-10-22 | 2005-05-12 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in tissues and organs |
US8034790B2 (en) * | 2003-12-01 | 2011-10-11 | Introgen Therapeutics | Use of MDA-7 to inhibit pathogenic infectious organisms |
KR20060132698A (en) * | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | Bis-indole pyrroles useful as antimicrobials agents |
AU2005219372A1 (en) * | 2004-02-13 | 2005-09-15 | Safeway Investments Ltd. | Therapeutic calcium phosphate particles and methods of making and using same |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
EP1766096B1 (en) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
US20080280973A1 (en) * | 2004-06-28 | 2008-11-13 | Wender Paul A | Laulimalide Analogues as Therapeutic Agents |
CN1733313A (en) * | 2004-08-11 | 2006-02-15 | 张阳德 | Process for preparing poly n-butyl cyan acrylate nanometer particle |
CN1732962A (en) * | 2004-08-11 | 2006-02-15 | 张阳德 | Process for preparing nanometer particle of adriacin-PACA-PBCA |
JP2008509933A (en) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | Pharmaceutical formulation comprising microparticles or nanoparticles of a delivery agent |
EP2359832A3 (en) | 2004-09-18 | 2011-11-23 | University of Maryland, Baltimore | Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
US7282194B2 (en) * | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US20090041812A1 (en) * | 2004-11-01 | 2009-02-12 | Bell Steve J D | Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use |
CN103230394B (en) * | 2004-12-03 | 2016-04-20 | 达纳-法伯癌症研究公司 | Compound for the treatment of neoplastic disease and uses thereof |
KR20070112155A (en) | 2005-02-08 | 2007-11-22 | 리서치 디벨럽먼트 파운데이션 | Compositions and methods related to soluble g-protein coupled receptors (sgpcrs) |
CA2597329C (en) * | 2005-02-08 | 2016-10-11 | Board Of Regents, The University Of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
ES2259914B1 (en) * | 2005-03-14 | 2007-06-16 | Advanced In Vitro Cell Technologies, S.L. | NANOPARTICULAS OF QUITOSANO AND POLYETHYLENE GLYCOL AS A SYSTEM OF ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES. |
CN101184504A (en) | 2005-03-31 | 2008-05-21 | 葛兰素史密丝克莱恩生物有限公司 | Vaccines against chlamydial infection |
ITMI20050739A1 (en) * | 2005-04-22 | 2006-10-23 | Effebi Spa | VALVE-ACTUATOR CONNECTION PLATE |
EP1883665B1 (en) | 2005-04-22 | 2017-10-11 | Universite De Geneve | Polylactide compositions and uses thereof |
CN101273055B (en) | 2005-04-29 | 2016-03-16 | 葛兰素史密丝克莱恩生物有限公司 | For preventing or treat the novel method of m tuberculosis infection |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
CA2608930A1 (en) * | 2005-06-14 | 2006-12-28 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
WO2007015757A2 (en) | 2005-07-21 | 2007-02-08 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
JPWO2007024026A1 (en) * | 2005-08-25 | 2009-03-05 | 明石 満 | Biodegradable nanoparticles having T cell recognition epitope peptide immobilized or encapsulated therein |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
CA2621982C (en) * | 2005-09-07 | 2017-11-28 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
CA2628630A1 (en) * | 2005-11-15 | 2007-05-24 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
CN101360422B (en) | 2005-11-23 | 2013-10-23 | 得克萨斯大学体系董事会 | Oncogenic Ras-specific cytotoxic compound and methods of usethereof |
EA201500845A1 (en) | 2005-11-28 | 2016-04-29 | Джи Ти Икс, ИНК. | AGENTS CONNECTING WITH NUCLEAR RECEPTORS |
EP1979488A4 (en) | 2006-01-09 | 2009-05-27 | Univ California | Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CN102026645B (en) | 2006-09-15 | 2016-01-27 | 渥太华医院研究机构 | Oncolytic rhabdovirus |
AU2007299748A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008070350A2 (en) | 2006-10-27 | 2008-06-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
CA2670320A1 (en) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of California | Modulation of rhamm (cd168) for selective adipose tissue development |
US20080138418A1 (en) * | 2006-12-07 | 2008-06-12 | Tong Shen Enterprise Co., Ltd. | Nanoparticles composed of alkyl-cyanoacrylate polymers |
EP3103451A1 (en) | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
US8679539B2 (en) * | 2007-01-31 | 2014-03-25 | Tong Shen Enterprise Co., Ltd. | Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof |
CA2677264C (en) | 2007-02-02 | 2021-11-30 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
KR20080084528A (en) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | Oncolytic vaccinia virus cancer therapy |
WO2008124647A2 (en) | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
PL2191001T3 (en) | 2007-04-09 | 2017-01-31 | University Of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
CA2963857A1 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
CA2974689C (en) | 2007-06-22 | 2020-02-25 | The United States Of America As Represented By The Department Of Veters Affairs | Inhibitors of ncca-atp channels for therapy |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
WO2009029686A1 (en) | 2007-08-27 | 2009-03-05 | Longhorn Vaccines & Diagnostics Llc | Immunogenic compositions and methods |
CL2008002775A1 (en) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
CN101896201A (en) * | 2007-12-14 | 2010-11-24 | 安进公司 | Method for treating bone fracture with anti-sclerostin antibodies |
US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
WO2009127060A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
JP2011516094A (en) | 2008-04-15 | 2011-05-26 | プロチバ バイオセラピューティクス インコーポレイティッド | Method for silencing CSN5 gene expression using interfering RNA |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
WO2009140287A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
JP5756751B2 (en) | 2008-06-26 | 2015-07-29 | エータイアー ファーマ, インコーポレイテッド | Compositions and methods comprising glycyl-tRNA synthetase with non-canonical biological activity |
US20110263478A1 (en) | 2008-09-16 | 2011-10-27 | Simard J Marc | Sur1 inhibitors for therapy |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
DK3255146T3 (en) | 2009-03-16 | 2019-08-19 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
AU2010236913B2 (en) | 2009-03-31 | 2016-03-24 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities |
JP2012524818A (en) | 2009-04-24 | 2012-10-18 | バンダービルト ユニバーシティ | Induction of bone cell function and bone growth by anti-TGF-β |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
ES2546526T3 (en) | 2009-07-24 | 2015-09-24 | Baylor College Of Medicine | Methods of modulation of branched chain acids and their uses |
US20120238509A1 (en) | 2009-08-28 | 2012-09-20 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
ES2848650T3 (en) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Combination cancer therapy with vaccinia oncolytic virus |
WO2011038160A2 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
AU2010329551B2 (en) | 2009-12-10 | 2016-02-11 | Turnstone Limited Partnership | Oncolytic rhabdovirus |
WO2011072266A2 (en) | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
EP2509625B1 (en) | 2009-12-11 | 2015-01-28 | Atyr Pharma, Inc. | Histidyl trna synthetases for reducing inflammation |
AU2010330794A1 (en) | 2009-12-18 | 2012-06-21 | Amgen Inc. | Wise binding agents and epitopes |
JP6010463B2 (en) | 2010-01-27 | 2016-10-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Modified tuberculosis antigen |
DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
LT2561067T (en) | 2010-04-23 | 2019-03-12 | University Of Florida Research Foundation, Inc. | Raav-guanylate cyclase compositions and methods for treating leber`s congenital amaurosis-1 (lca1) |
EP2560624B1 (en) | 2010-04-23 | 2018-07-04 | KemPharm, Inc. | Therapeutic formulation for reduced drug side effects |
WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
JP6294074B2 (en) | 2010-04-27 | 2018-03-14 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase |
CA2797271C (en) | 2010-04-28 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
CN103097523B (en) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds |
CA2797393C (en) | 2010-04-29 | 2020-03-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
ES2668207T3 (en) | 2010-05-03 | 2018-05-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic and antibody compositions related to fragments of methionyl-tRNA synthetases proteins |
AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
CN103096925A (en) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases |
CN102985103A (en) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
CA2799091A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
ME02819B (en) | 2010-05-14 | 2018-01-20 | Amgen Inc | High concentration antibody formulations |
US8945541B2 (en) | 2010-05-14 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
CA2799480C (en) | 2010-05-17 | 2020-12-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
EP2575856B1 (en) | 2010-05-27 | 2017-08-16 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
EP2575857B1 (en) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
WO2012021247A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
EP2606152B1 (en) | 2010-08-18 | 2016-10-05 | Fred Hutchinson Cancer Research Center | Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd) |
CA2808539C (en) | 2010-08-25 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
US20130345079A1 (en) | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
WO2012064659A1 (en) | 2010-11-08 | 2012-05-18 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
CN103429258B (en) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | By use oncolytic vaccinia virus generate for tumor antigen antibody and generate tumour-specific CDC |
KR20140038358A (en) | 2011-01-11 | 2014-03-28 | 페이트 세러퓨틱스, 인코포레이티드 | Novel wnt compositions and therapeutic uses of such compositions |
WO2012103328A1 (en) | 2011-01-26 | 2012-08-02 | The Methodist Hospital Research Institute | Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use |
JP2014506791A (en) | 2011-02-03 | 2014-03-20 | マーナ セラピューティクス インコーポレイテッド | miR-34 synthetic mimics |
WO2012106586A1 (en) | 2011-02-03 | 2012-08-09 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
US8986739B2 (en) | 2011-02-28 | 2015-03-24 | Nicholas V. Perricone | Treatment of urinary incontinence using nitrone spin traps |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
EA029956B1 (en) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Anti-sclerostin antibody crystals and formulations thereof |
WO2012133648A1 (en) | 2011-03-31 | 2012-10-04 | Shirotake Shoichi | Novel preparation technique for higher-order structure that exhibits anti-cellular effect |
EP2699261B1 (en) | 2011-04-19 | 2018-07-11 | Amgen Inc. | Method for treating osteoporosis |
WO2012167382A1 (en) | 2011-06-08 | 2012-12-13 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
CA2838749A1 (en) | 2011-06-10 | 2012-12-13 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
MX2013013627A (en) | 2011-06-21 | 2014-04-25 | Oncofactor Corp | Compositions and methods for the therapy and diagnosis of cancer. |
EP3628325A1 (en) | 2011-07-22 | 2020-04-01 | The University of Chicago | Treatments for migraine and related disorders |
WO2013019954A1 (en) | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
WO2013057592A2 (en) | 2011-09-14 | 2013-04-25 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
WO2013041969A2 (en) | 2011-09-21 | 2013-03-28 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in tistrella mobilis |
US9783822B2 (en) | 2011-09-23 | 2017-10-10 | Bluebird Bio, Inc. | Gene therapy methods |
WO2013095736A2 (en) | 2011-09-27 | 2013-06-27 | The Methodist Hospital Research Institute | Gold-in-silicon nanoassembly for thermal therapy and methods of use |
MX359398B (en) | 2011-09-30 | 2018-09-27 | Bluebird Bio Inc | Compounds for improved viral transduction. |
WO2013059676A1 (en) | 2011-10-21 | 2013-04-25 | Subhash Desai | Compositions for reduction of side effects |
CN104136026B (en) | 2011-10-31 | 2018-03-02 | 卫理公会医院研究所 | Human glioma comprising MAO targetings/seeker part, which treats, uses compound |
CN107880101B (en) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | T cell immunotherapy targeting cyclin A1 against cancer |
EP2785184B1 (en) | 2011-11-30 | 2020-06-10 | Emory University | Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv |
US9546367B2 (en) | 2011-12-07 | 2017-01-17 | Jenny Chee Ning Chang | siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
KR20190120401A (en) | 2011-12-28 | 2019-10-23 | 암젠 인크 | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
WO2013123282A1 (en) | 2012-02-16 | 2013-08-22 | The University Of Toledo | Xenoantigen-displaying anti-cancer vaccines and method of making |
DK2817287T3 (en) | 2012-02-24 | 2019-01-02 | Arbutus Biopharma Corp | TRIALKYL CATIONIC LIPID AND METHODS FOR USING IT |
AR092821A1 (en) | 2012-04-20 | 2015-05-06 | Sucampo Ag | CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE |
US20160015824A1 (en) | 2012-05-23 | 2016-01-21 | Ohio State Innovation Foundation | Lipid-Coated Albumin Nanoparticle Compositions and Methods of Making and Method of Using the Same |
AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
HRP20240164T1 (en) | 2012-08-03 | 2024-04-12 | Access To Advanced Health Institute | Compositions and methods for treating an active mycobacterium tuberculosis infection |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
RU2684211C2 (en) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Vaccine composition |
US10208012B2 (en) | 2013-03-13 | 2019-02-19 | Board Of Regents, The University Of Texas System | Compounds for treating inflammatory and hyperproliferative diseases |
BR112015024860B1 (en) | 2013-03-28 | 2023-11-07 | Access To Advanced Health Institute | FUSION POLYPEPTIDE, ISOLATED POLYNUCLEOTIDE, COMPOSITION COMPRISING SAID POLYPEPTIDE, USE OF SAID COMPOSITION TO STIMULATE AN IMMUNE RESPONSE AGAINST LEISHMANIA AND IN VITRO METHOD AND DIAGNOSTIC KIT FOR DETECTING LEISHMANIA INFECTION IN A BIOLOGICAL SPECIMEN |
WO2014186746A1 (en) | 2013-05-16 | 2014-11-20 | University Of Florida Research Foundation, Inc. | HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION |
WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
JP6657101B2 (en) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | Compounds for the treatment of diabetes and disease complications resulting therefrom |
AU2014357521B2 (en) | 2013-12-02 | 2018-10-11 | Baylor College Of Medicine | Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose |
WO2015138919A1 (en) | 2014-03-14 | 2015-09-17 | The University Of North Carolina At Chapel Hill | Small molecules for inhibiting male fertility |
CN106572988B (en) | 2014-04-08 | 2022-04-08 | 卫理公会医院 | INOS inhibitory composition and use thereof as breast cancer therapeutic agent |
WO2015157500A1 (en) | 2014-04-09 | 2015-10-15 | Research Development Foundation | Class iia hdac inhibitors for the treatment of infection |
US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
BR112016029820A2 (en) | 2014-06-20 | 2017-10-24 | Aveo Pharmaceuticals Inc | treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
WO2016025202A1 (en) | 2014-08-14 | 2016-02-18 | The Regents Of The University Of Colorado | Antibody-sirna conjugates and uses therefor |
WO2016036727A1 (en) | 2014-09-01 | 2016-03-10 | Academia Sinica | Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis |
CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
WO2016037138A1 (en) | 2014-09-04 | 2016-03-10 | Memorial Sloan-Kettering Cancer Center | Global gene therapy for treating hemoglobinopathies |
US20170306008A1 (en) | 2014-09-25 | 2017-10-26 | Aveo Pharmaceuticals, Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
KR20170075742A (en) | 2014-10-02 | 2017-07-03 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | Compositions and methods for silencing hepatitis b virus gene expression |
JP6842410B2 (en) | 2014-10-03 | 2021-03-17 | ユニバーシティ オブ マサチューセッツ | AAV vector identified by a novel high efficiency library |
CA2963923A1 (en) | 2014-10-08 | 2016-04-14 | Pacific Northwest Research Institute | Methods and compounds for increasing the potency of antifungal agents |
CN107073051B (en) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | Recombinant AAV variants and uses thereof |
WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
EP3233131A1 (en) | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gene therapy for juvenile batten disease |
CA2978917A1 (en) | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression |
US11285190B2 (en) | 2015-04-20 | 2022-03-29 | The Board Of Regents Of The University Of Texas System | CLEC11a is a bone growth agent |
CA3019315A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
WO2016205615A1 (en) | 2015-06-17 | 2016-12-22 | The Johns Hopkins University | Tdp-43 in degenerative disease |
CN108350455A (en) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | Composition for making hepatitis B virus silenced gene expression and method |
US20170056485A1 (en) | 2015-08-31 | 2017-03-02 | Sciotec Diagnostic Technologies Gmbh | Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease |
DK3364997T3 (en) | 2015-10-22 | 2024-04-22 | Univ Massachusetts | ASPARTOACYLASE GENE THERAPY FOR THE TREATMENT OF CANAVAN'S DISEASE |
WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
CN108884448B (en) | 2016-01-27 | 2022-12-30 | 昂克诺斯公司 | Oncolytic viral vectors and uses thereof |
US10695322B2 (en) | 2016-01-29 | 2020-06-30 | The Johns Hopkins University | Inhibitors of bacterial growth |
CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
US11040025B2 (en) | 2016-02-17 | 2021-06-22 | The Johns Hopkins University | Oxazolidinone for treatment of infections with Mycobacterium tuberculosis |
US11149060B2 (en) | 2016-02-19 | 2021-10-19 | University Of Delaware | Functionalized nanoparticles for enhanced affinity precipitation of proteins |
WO2017147215A1 (en) | 2016-02-22 | 2017-08-31 | The Methodist Hospital | Biomimetic proteolipid vesicle compositions and uses thereof |
WO2017147370A1 (en) | 2016-02-24 | 2017-08-31 | The Johns Hopkins University | Novel antiviral proteins and their uses in therapeutic methods |
JP2019511483A (en) | 2016-03-02 | 2019-04-25 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | STING activated nanovaccine for immunotherapy |
RU2752882C2 (en) | 2016-03-03 | 2021-08-11 | Юниверсити Оф Массачусетс | Closed-end linear duplex dna for non-viral gene transfer |
US10888549B2 (en) | 2016-03-07 | 2021-01-12 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
US11965009B2 (en) | 2016-03-10 | 2024-04-23 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
BR112018068055A2 (en) | 2016-03-10 | 2019-01-08 | Univ Johns Hopkins | methods for producing aggregate free monomeric diphtheria toxin fusion proteins and therapeutic uses |
KR20230038214A (en) | 2016-03-17 | 2023-03-17 | 더 존스 홉킨스 유니버시티 | Methods for preventing or treating parkinson's disease by the farnesylation of paris |
WO2017173055A1 (en) | 2016-03-30 | 2017-10-05 | The Johns Hopkins University | Olfr90 specificity and methods of detection |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
CN109310748A (en) | 2016-05-21 | 2019-02-05 | 传染病研究所 | For treating the composition and method of secondary tuberculosis and non-tuberculous mycobacteria infection |
WO2018006052A1 (en) | 2016-06-30 | 2018-01-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
KR20190096329A (en) | 2016-07-05 | 2019-08-19 | 유니버시티 오브 매사추세츠 | AAV2-mediated gene delivery of SFASL as a neuroprotective therapy in glaucoma |
AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
WO2018035429A1 (en) | 2016-08-18 | 2018-02-22 | Wisconsin Alumni Research Foundation | Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r |
US11801290B2 (en) | 2016-09-16 | 2023-10-31 | Access To Advanced Health Institute | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
US11149275B2 (en) | 2016-10-10 | 2021-10-19 | The Johns Hopkins University | Device and method to treat esophageal disorders |
US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
WO2018140826A1 (en) | 2017-01-27 | 2018-08-02 | The Methodist Hospital | Core/shell structure platform for immunotherapy |
CN110505872A (en) | 2017-02-12 | 2019-11-26 | 本古里安大学内盖夫研究和发展局 | Telomerase activation compound for fertility and related application |
EP3619299A1 (en) | 2017-05-03 | 2020-03-11 | BioMarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
MX2019014760A (en) | 2017-06-06 | 2020-08-03 | Univ Massachusetts | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome. |
EP3652540A4 (en) | 2017-07-12 | 2021-04-07 | The Johns Hopkins University | A proteoliposome-based znt8 self-antigen for type 1 diabetes diagnosis |
EP3658165A4 (en) | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
WO2019028469A1 (en) | 2017-08-04 | 2019-02-07 | The Methodist Hospital | Polymer-functionalized mitochondrial compositions and methods of use in cellular transplantation and for altering metabolic phenotype |
JP7339942B2 (en) | 2017-09-08 | 2023-09-06 | アクセス ツー アドバンスト ヘルス インスティチュート | Liposomal formulation containing saponin and method of use |
WO2019099613A1 (en) | 2017-11-16 | 2019-05-23 | University Of Maine System Board Of Trustees | Compositions and methods for modulating endothelial cell migration and angiogenesis |
EP3720509A4 (en) | 2017-12-06 | 2021-12-08 | Memorial Sloan-Kettering Cancer Center | Globin gene therapy for treating hemoglobinopathies |
WO2019118806A1 (en) | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
US11246857B2 (en) | 2017-12-14 | 2022-02-15 | The Johns Hopkins University | Anti-fungal inhibitors |
WO2019134049A1 (en) | 2018-01-05 | 2019-07-11 | Bell John C | Modified vaccinia vectors |
EP3768698A4 (en) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
JP2021519065A (en) | 2018-03-23 | 2021-08-10 | ユニバーシティ オブ マサチューセッツ | Gene therapy to treat bone disorders |
EP3773612A4 (en) | 2018-03-28 | 2022-01-12 | Herbalife International of America, Inc. | Acetylation of polysaccharides |
SG11202008206TA (en) | 2018-03-30 | 2020-09-29 | Amgen Inc | C-terminal antibody variants |
EP3784290A4 (en) | 2018-04-27 | 2022-03-23 | University of Massachusetts | Aav capsids identified by in vivo library selection |
EP3790394A4 (en) | 2018-05-08 | 2022-07-27 | Rutgers, the State University of New Jersey | Aav-compatible laminin-linker polymerization proteins |
KR102167755B1 (en) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | Fragmented GRS polypeptide, mutants thereof and use thereof |
CN113164625A (en) | 2018-09-28 | 2021-07-23 | 哈佛大学的校长及成员们 | Mutant inverse tetracycline transactivators for gene expression |
EP3856226A1 (en) | 2018-09-28 | 2021-08-04 | President and Fellows of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
CN113557035A (en) | 2019-01-12 | 2021-10-26 | 卫理公会医院 | Self-assembling peptide nanoparticles and uses thereof |
WO2020163766A1 (en) | 2019-02-07 | 2020-08-13 | Baylor College Of Medicine | Periosteal skeletal stem cells in bone repair |
US20220054655A1 (en) | 2019-02-22 | 2022-02-24 | University Of Massachusetts | Oxr1 gene therapy |
US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
CN114555814A (en) | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | AAV-compatible laminin-linker polyproteins |
US20220380735A1 (en) | 2019-10-10 | 2022-12-01 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
WO2021076656A1 (en) | 2019-10-15 | 2021-04-22 | University Of Massachusetts | Rna editor-enhanced rna trans-splicing |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
US20230348624A1 (en) | 2020-01-30 | 2023-11-02 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
MX2022012279A (en) | 2020-03-31 | 2023-02-23 | Univ Massachusetts | Aav capsids variants and uses thereof. |
US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
US20230287038A1 (en) | 2020-08-07 | 2023-09-14 | Access To Advanced Health Institute | Purified saponins and chromatographic process for purification of same |
KR20230117177A (en) | 2020-12-03 | 2023-08-07 | 유니버시티 오브 매사추세츠 | Development of novel gene therapy for progressive ossifying fibrous dysplasia |
KR20220082558A (en) | 2020-12-10 | 2022-06-17 | 재단법인 의약바이오컨버젼스연구단 | Novel fragmented cysteinyl-tRNA synthetase peptide with immune-enhancing activity and use thereof |
EP4284821A1 (en) | 2021-01-27 | 2023-12-06 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
WO2023144393A1 (en) | 2022-01-28 | 2023-08-03 | Fundació Centre De Regulació Genòmica | Therapeutic cytokines and methods |
WO2023144792A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023215481A1 (en) | 2022-05-05 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064967A1 (en) * | 1981-04-24 | 1982-11-17 | N.V. Sopar S.A. | Process for producing submicroscopic particles, particles obtained in that way and pharmaceutical compositions containing them |
WO1994017789A1 (en) * | 1993-02-15 | 1994-08-18 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
-
1995
- 1995-04-04 IE IE950237A patent/IE80468B1/en not_active IP Right Cessation
- 1995-06-07 US US08/474,161 patent/US5641515A/en not_active Expired - Lifetime
-
1996
- 1996-04-02 EP EP96909320A patent/EP0820300B1/en not_active Expired - Lifetime
- 1996-04-02 DE DE69631824T patent/DE69631824T2/en not_active Expired - Lifetime
- 1996-04-02 WO PCT/IE1996/000018 patent/WO1996031231A1/en active IP Right Grant
- 1996-04-02 JP JP53015796A patent/JP3981152B2/en not_active Expired - Fee Related
- 1996-04-02 CA CA002217485A patent/CA2217485C/en not_active Expired - Fee Related
- 1996-04-02 AT AT96909320T patent/ATE261311T1/en active
- 1996-04-02 ES ES96909320T patent/ES2213770T3/en not_active Expired - Lifetime
- 1996-04-02 NZ NZ304976A patent/NZ304976A/en not_active IP Right Cessation
- 1996-04-02 DK DK96909320T patent/DK0820300T3/en active
- 1996-04-02 AU AU52867/96A patent/AU704875B2/en not_active Ceased
- 1996-04-02 PT PT96909320T patent/PT820300E/en unknown
- 1996-04-03 ZA ZA962671A patent/ZA962671B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064967A1 (en) * | 1981-04-24 | 1982-11-17 | N.V. Sopar S.A. | Process for producing submicroscopic particles, particles obtained in that way and pharmaceutical compositions containing them |
WO1994017789A1 (en) * | 1993-02-15 | 1994-08-18 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002504526A (en) * | 1998-02-27 | 2002-02-12 | バイオオーリアンス ファーマ(エス.エー.) | Nanoparticles comprising at least one polymer and at least one compound capable of complexing with one or more active ingredients |
JP4651192B2 (en) * | 1998-02-27 | 2011-03-16 | バイオオーリアンス ファーマ(エス.エー.) | Nanoparticles comprising at least one polymer and at least one compound capable of forming a complex with one or more active ingredients and method for producing the same |
US6770276B1 (en) | 1999-11-30 | 2004-08-03 | Otkrytoe Aktsionernoe Obschestvo “Quantum Satis” | Insulin-containing medicament for peroral application and method for the production thereof |
WO2001039794A1 (en) * | 1999-11-30 | 2001-06-07 | Oao 'quantum Satis' | Insulin-containing medicament for peroral application and method for the production thereof |
US6582713B2 (en) | 2000-04-06 | 2003-06-24 | Univ. Of Colorado - Colorado Springs | Compositions and methods for promoting wound healing |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US7879588B2 (en) | 2003-10-02 | 2011-02-01 | Ascendis Pharma A/S | Protein-proteophore complexes |
EP2090323A1 (en) | 2003-10-02 | 2009-08-19 | Complex Biosystems GmbH | Protein-Proteophor Complexes |
WO2005034909A3 (en) * | 2003-10-02 | 2005-12-08 | Complex Biosystems Gmbh | Hyperbranched polymer conjugates via non-enzymatic cleavable linker |
EP1525890A1 (en) * | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
WO2005034909A2 (en) * | 2003-10-02 | 2005-04-21 | Complex Biosystems Gmbh | Hyperbranched polymer conjugates via non-enzymatic cleavable linker |
EP3085388A1 (en) * | 2003-10-02 | 2016-10-26 | Ascendis Pharma Growth Disorders Division A/S | Hyperbranched polymer conjugates via non-enzymatic cleavable linker |
US8450097B2 (en) | 2003-10-02 | 2013-05-28 | Ascendis Pharma Gmbh | Protein-proteophore complexes |
WO2006016020A3 (en) * | 2004-07-07 | 2006-07-13 | Ethypharm Sa | Nanoparticles comprising a core essentially consisting of a cyanoacrylic polymer and a shell of an amphiphilic polymer and, optionally, an active principle, preferably bisulfan |
WO2006016020A2 (en) * | 2004-07-07 | 2006-02-16 | Ethypharm | Nanoparticles comprising a core essentially consisting of a cyanoacrylic polymer and a shell of an amphiphilic polymer and, optionally, an active principle, preferably bisulfan |
FR2872703A1 (en) * | 2004-07-07 | 2006-01-13 | Ethypharm Sa | COMPOSITE POLYMERIC NANOPARTICLES |
WO2008003706A1 (en) * | 2006-07-04 | 2008-01-10 | Nanodel Technologies Gmbh | Two step miniemulsion process |
EP2236143A1 (en) * | 2007-12-27 | 2010-10-06 | Public University Corporation Yokohama City University | Antimicrobial agent for gram-positive bacteria |
EP2236143A4 (en) * | 2007-12-27 | 2011-01-05 | Public Univ Corp Yokohama City | Antimicrobial agent for gram-positive bacteria |
EP2285825A1 (en) * | 2008-05-09 | 2011-02-23 | South Dakota State University | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
AU2009244742B2 (en) * | 2008-05-09 | 2014-11-06 | South Dakota State University | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
EP2285825A4 (en) * | 2008-05-09 | 2012-11-28 | Univ South Dakota | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
CN102066399A (en) * | 2008-05-09 | 2011-05-18 | 南达科他州立大学 | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
EP2805617A4 (en) * | 2012-01-19 | 2015-08-12 | Shoichi Shirotake | Antibacterial agent against plant disease-causing bacteria |
WO2013171570A1 (en) * | 2012-05-16 | 2013-11-21 | Glaxo Group Limited | Polypeptide loaded poca nanoparticles for oral administration |
CN104411321A (en) * | 2012-05-16 | 2015-03-11 | 葛兰素集团有限公司 | Polypeptide loaded poca nanoparticles for oral administration |
US20150342897A1 (en) * | 2012-05-16 | 2015-12-03 | Glaxo Group Limited | Polypeptide loaded poca nanoparticles for oral administration |
WO2014027254A1 (en) * | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
WO2014027253A1 (en) * | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
US10351644B2 (en) | 2014-02-27 | 2019-07-16 | Shoichi Shirotake | Antiviral drug |
Also Published As
Publication number | Publication date |
---|---|
ATE261311T1 (en) | 2004-03-15 |
AU704875B2 (en) | 1999-05-06 |
NZ304976A (en) | 1999-04-29 |
CA2217485C (en) | 2009-10-13 |
DE69631824T2 (en) | 2005-01-27 |
US5641515A (en) | 1997-06-24 |
IE950237A1 (en) | 1996-10-16 |
EP0820300A1 (en) | 1998-01-28 |
DK0820300T3 (en) | 2004-04-26 |
PT820300E (en) | 2004-07-30 |
AU5286796A (en) | 1996-10-23 |
ES2213770T3 (en) | 2004-09-01 |
DE69631824D1 (en) | 2004-04-15 |
JPH11503148A (en) | 1999-03-23 |
EP0820300B1 (en) | 2004-03-10 |
CA2217485A1 (en) | 1996-10-10 |
JP3981152B2 (en) | 2007-09-26 |
ZA962671B (en) | 1996-10-09 |
IE80468B1 (en) | 1998-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0820300B1 (en) | Controlled release biodegradable nanoparticles containing insulin | |
CA2592991C (en) | Nanoparticles for protein drug delivery | |
US7291598B2 (en) | Nanoparticles for protein drug delivery | |
Damgé et al. | New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier | |
US7858596B2 (en) | Nanoparticles for protein drug delivery | |
US6645525B1 (en) | Ionically formulated biomolecule microcarriers | |
US7381716B2 (en) | Nanoparticles for protein drug delivery | |
US7611690B2 (en) | Nanoparticles for protein drug delivery | |
Jin et al. | Chitosan–glutathione conjugate-coated poly (butyl cyanoacrylate) nanoparticles: promising carriers for oral thymopentin delivery | |
US20100143484A1 (en) | Oral submicron particle delivery system for proteins and process for its production | |
WO2007036946A1 (en) | Compositions for enhanced absorption of biologically active agents | |
LT et al. | Manufacturing Co. 11710 Naor (JO) | |
Badwan et al. | Nanocapsules for oral delivery of proteins | |
Shalaby et al. | Implantable insulin controlled release systems for treating diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2217485 Country of ref document: CA Ref country code: CA Ref document number: 2217485 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1996 530157 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996909320 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 304976 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996909320 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996909320 Country of ref document: EP |